Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alwin D R Huitema

Showing results (1-10 of 443) with videos related to

Pageof 45
Sort By:
Cancer Chemotherapy and Pharmacology|September 20, 2022
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatmentKarlijn Verkerk, Hans-Martin Otten, Alwin D R Huitema
Expert Opinion on Pharmacotherapy|April 21, 2010
Treatment of HIV infection with the CCR5 antagonist maravirocWiete Kromdijk, Alwin D R Huitema, Jan Willem Mulder
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Individualized Pazopanib Dosing-ResponseRemy B Verheijen, Alwin D R Huitema, Neeltje Steeghs
Human Antibodies|December 10, 2009
The preparation of radiolabeled monoclonal antibodies for human useLy Tran, Jos H Beijnen, Alwin D R Huitema
Drugs in R&D|March 22, 2005
Should non-nucleoside reverse transcriptase inhibitors be combined?Bregt S Kappelhoff, Alwin D R Huitema, Jos H Beijnen
Anti-Cancer Drugs|February 2, 2023
Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumorsMaarten van Eijk, Jos H Beijnen, Alwin D R Huitema
Cancer Chemotherapy and Pharmacology|April 26, 2008
Carbamazepine induces bioactivation of cyclophosphamide and thiotepaCorine Ekhart, Sjoerd Rodenhuis, Jos H Beijnen, et al.
Therapeutic Drug Monitoring|January 22, 2009
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimenCorine Ekhart, Sjoerd Rodenhuis, Jos H Beijnen, et al.
BMC Cancer|December 5, 2018
Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levelsStefanie L Groenland, Daniela Katz, Alwin D R Huitema, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 12, 2021
Stability study of concentrate-solvent mixture & infusion solutions of Jevtana® cabazitaxel for extended multi-dosingA Hedvig Arnamo, Alwin D R Huitema, Jos H Beijnen, et al.
Pageof 45

Showing results (1-10 of 443) with videos related to

Sort By:
Pageof 45
Cancer Chemotherapy and Pharmacology|September 20, 2022
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatmentKarlijn Verkerk, Hans-Martin Otten, Alwin D R Huitema
Expert Opinion on Pharmacotherapy|April 21, 2010
Treatment of HIV infection with the CCR5 antagonist maravirocWiete Kromdijk, Alwin D R Huitema, Jan Willem Mulder
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2016
Individualized Pazopanib Dosing-ResponseRemy B Verheijen, Alwin D R Huitema, Neeltje Steeghs
Human Antibodies|December 10, 2009
The preparation of radiolabeled monoclonal antibodies for human useLy Tran, Jos H Beijnen, Alwin D R Huitema
Drugs in R&D|March 22, 2005
Should non-nucleoside reverse transcriptase inhibitors be combined?Bregt S Kappelhoff, Alwin D R Huitema, Jos H Beijnen
Anti-Cancer Drugs|February 2, 2023
Time above threshold plasma concentrations as pharmacokinetic parameter in the comparison of oral and intravenous docetaxel treatment of breast cancer tumorsMaarten van Eijk, Jos H Beijnen, Alwin D R Huitema
Cancer Chemotherapy and Pharmacology|April 26, 2008
Carbamazepine induces bioactivation of cyclophosphamide and thiotepaCorine Ekhart, Sjoerd Rodenhuis, Jos H Beijnen, et al.
Therapeutic Drug Monitoring|January 22, 2009
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimenCorine Ekhart, Sjoerd Rodenhuis, Jos H Beijnen, et al.
BMC Cancer|December 5, 2018
Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levelsStefanie L Groenland, Daniela Katz, Alwin D R Huitema, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 12, 2021
Stability study of concentrate-solvent mixture & infusion solutions of Jevtana® cabazitaxel for extended multi-dosingA Hedvig Arnamo, Alwin D R Huitema, Jos H Beijnen, et al.
Pageof 45